Pfizer Vfend Approved For Candidemia
This article was originally published in The Pink Sheet Daily
Supplemental indication is based on trial showing voriconazole was as effective as a regimen of amphotericin B followed by fluconazole. Pfizer may try to differentiate the product based on adverse event profile.
You may also be interested in...
FDA approves numerous ANDAs for tablet, oral suspension and injectable forms of the antifungal upon expiration of Diflucan's six-month pediatric extension. Pfizer is marketing its own generic through its Greenstone subsidiary.
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles